DNA

RhoVac

Spotlight Stockholm: RHOVAC

SEK304.8m market cap

SEK16 last close

RhoVac is an immunotherapy company listed on the Spotlight Stock Market in Sweden, with a 100%-owned subsidiary in Denmark. It is currently developing a peptide-based immunotherapy, RV001, which aims to train the immune system to specifically target cancer cells with metastatic potential.

Investment summary

RhoVac is developing RV001, a cancer immunotherapy designed to prevent or limit metastasis by activating T-cells against cells with metastatic potential. The therapy contains fragments of the protein RhoC, which is overexpressed in cells with metastatic potential across a range of cancers. The recently raised SEK154m net will be used for a Phase IIb study in prostate cancer (results in H221) and a potential exploratory Phase II combination study in other cancers. RhoVac’s strategic aim is to secure a partner for the late-stage development of RV001.

Y/E Dec
Revenue (SEKm)
EBITDA (SEKm)
PBT (SEKm)
EPS (öre)
P/E (x)
P/CF (x)
2017A 0.0 (12.9) (12.9) (134.22) N/A N/A
2018A 0.0 (20.1) (20.2) (194.94) N/A N/A
2019E 0.0 (50.0) (49.6) (347.33) N/A N/A
2020E 0.0 (60.0) (59.4) (311.98) N/A N/A
Last updated on 17/10/2019
Industry outlook

Metastatic cancer is the most advanced stage of cancer and is terminal. Unfortunately, a large proportion of patients who are diagnosed with cancer already have metastases. Preventing or halting metastasis through inhibiting the metastatic cascade or selectively killing cells with metastatic potential could help to improve survival.

Last updated on 17/10/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (SEKm) 150.8
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 1.1 (7.0) (59.5)
Relative* 1.1 (8.7) (56.8)
52-week high/low SEK42.2/SEK15.2
*% relative to local index
Key management
Anders Månsson CEO
Alexandra Ellervik IR
Anders Ljungqvist COO